Chemotherapy Drugs Categorized as ‘In-Office Ancillary Services’

Publication
Article
OncologyONCOLOGY Vol 15 No 4
Volume 15
Issue 4

Not only has the Health Care Financing Administration (HCFA) backed off on threats to reduce Medicare and Medicaid payments to oncologists for in-office chemotherapy infusion drugs, but now HCFA is making it clear that oncologists can

Not only has the Health Care Financing Administration (HCFA)backed off on threats to reduce Medicare and Medicaid paymentsto oncologists for in-office chemotherapy infusion drugs, but now HCFA is makingit clear that oncologists can provide those drugs to patients without runningafoul of federal self-referral rules. Those rules actually became law in 1993thanks to Rep. Pete Stark (D-Calif), who sponsored the bill that made it illegalfor physicians to refer patients for 10 categories of medical services if thephysician or a member of his family had a financial interest in that serviceprovider. An exception was made for physicians referring patients intra-officefor ancillary services, but when HCFA issued the proposed rule a few years ago,it was unclear whether chemotherapy drugs would be included in the exemption.When HCFA issued the final rules this past January, it was clearly explainedthat chemotherapy infusion drugs were to be considered exempt.

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.